WO1999017809A3 - Contrast-enhanced diagnostic imaging method for monitoring interventional therapies - Google Patents
Contrast-enhanced diagnostic imaging method for monitoring interventional therapies Download PDFInfo
- Publication number
- WO1999017809A3 WO1999017809A3 PCT/US1998/020182 US9820182W WO9917809A3 WO 1999017809 A3 WO1999017809 A3 WO 1999017809A3 US 9820182 W US9820182 W US 9820182W WO 9917809 A3 WO9917809 A3 WO 9917809A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- contrast
- tissue
- diagnostic imaging
- imaging method
- state
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 238000002059 diagnostic imaging Methods 0.000 title abstract 2
- 238000012544 monitoring process Methods 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000002872 contrast media Substances 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
Abstract
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98950704A EP1019094B1 (en) | 1997-10-02 | 1998-09-24 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
SK484-2000A SK4842000A3 (en) | 1997-10-02 | 1998-09-24 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
JP2000514677A JP2001518523A (en) | 1997-10-02 | 1998-09-24 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapy |
AT98950704T ATE254479T1 (en) | 1997-10-02 | 1998-09-24 | METHOD FOR IMPROVED CONTRAST IMAGING FOR THERAPY MONITORING |
DK98950704T DK1019094T3 (en) | 1997-10-02 | 1998-09-24 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
DE69819925T DE69819925T2 (en) | 1997-10-02 | 1998-09-24 | Contrast-enhanced diagnostic image generation method for monitoring therapeutic interventions |
AU96686/98A AU742438C (en) | 1997-10-02 | 1998-09-24 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
BR9812716-0A BR9812716A (en) | 1997-10-02 | 1998-09-24 | Imaging methods for enhanced contrast diagnosis to monitor interventional therapies |
KR1020007003527A KR20010030854A (en) | 1997-10-02 | 1998-09-24 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
IL13498598A IL134985A0 (en) | 1997-10-02 | 1998-09-24 | A method for contrast enhanced diagnostic imaging |
NZ503402A NZ503402A (en) | 1997-10-02 | 1998-09-24 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
HU0101245A HUP0101245A3 (en) | 1997-10-02 | 1998-09-24 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
CA002303426A CA2303426C (en) | 1997-10-02 | 1998-09-24 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
IS5399A IS2041B (en) | 1997-10-02 | 2000-03-10 | Shadow-enhancing imaging method to monitor the intervention |
NO20001707A NO321966B1 (en) | 1997-10-02 | 2000-04-03 | Use of a contrast agent for the preparation of a diagnostic agent for monitoring image contrast during intervention therapy. |
HK01100360A HK1030744A1 (en) | 1997-10-02 | 2001-01-12 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94298997A | 1997-10-02 | 1997-10-02 | |
US08/942,989 | 1997-10-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999017809A2 WO1999017809A2 (en) | 1999-04-15 |
WO1999017809A3 true WO1999017809A3 (en) | 1999-05-20 |
Family
ID=25478927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/020182 WO1999017809A2 (en) | 1997-10-02 | 1998-09-24 | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
Country Status (20)
Country | Link |
---|---|
US (2) | US6861045B1 (en) |
EP (1) | EP1019094B1 (en) |
JP (2) | JP2001518523A (en) |
KR (1) | KR20010030854A (en) |
AT (1) | ATE254479T1 (en) |
AU (1) | AU742438C (en) |
BR (1) | BR9812716A (en) |
CA (1) | CA2303426C (en) |
DE (1) | DE69819925T2 (en) |
DK (1) | DK1019094T3 (en) |
ES (1) | ES2206996T3 (en) |
HK (1) | HK1030744A1 (en) |
HU (1) | HUP0101245A3 (en) |
IL (1) | IL134985A0 (en) |
IS (1) | IS2041B (en) |
NO (1) | NO321966B1 (en) |
NZ (1) | NZ503402A (en) |
PT (1) | PT1019094E (en) |
SK (1) | SK4842000A3 (en) |
WO (1) | WO1999017809A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9295737B2 (en) | 2002-03-01 | 2016-03-29 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
US9408926B2 (en) | 2002-03-01 | 2016-08-09 | Bracco Suisse S.A. | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US9446155B2 (en) | 2002-03-01 | 2016-09-20 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495118B1 (en) | 1997-09-26 | 2002-12-17 | Schering Aktiengesellschaft | Lipophilic metal complexes for necrosis and infarction imaging |
AU742438C (en) * | 1997-10-02 | 2003-05-22 | Lantheus Medical Imaging, Inc. | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
US6167297A (en) * | 1999-05-05 | 2000-12-26 | Benaron; David A. | Detecting, localizing, and targeting internal sites in vivo using optical contrast agents |
US6548044B1 (en) | 1999-11-22 | 2003-04-15 | Epix Medical, Inc. | Imaging sexual response |
JP2003520255A (en) * | 2000-01-22 | 2003-07-02 | エピックス メディカル, インコーポレイテッド | Magnetic resonance imaging using contrast agent prodrugs that are bioactivated by enzymatic cleavage |
TWI221406B (en) | 2001-07-30 | 2004-10-01 | Epix Medical Inc | Systems and methods for targeted magnetic resonance imaging of the vascular system |
EP1423136A4 (en) * | 2001-08-10 | 2007-07-25 | Epix Pharm Inc | Polypeptide conjugates with extended circulating half-lives |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
ES2398393T3 (en) | 2002-03-01 | 2013-03-15 | Dyax Corp. | KDR and VEGF / KDR binding peptides and their use in diagnosis and therapy |
ES2396368T3 (en) | 2003-03-03 | 2013-02-21 | Dyax Corporation | Peptides that specifically bind to the HGF receptor (CMET) and uses thereof |
US20050064045A1 (en) * | 2003-09-18 | 2005-03-24 | Sheng-Ping Zhong | Injectable therapeutic formulations |
WO2005110495A1 (en) * | 2004-05-18 | 2005-11-24 | Siemens Aktiengesellschaft | Biomolecular contrast agents for therapy control in radiation therapy with proton or ion beams |
US7585492B2 (en) | 2004-05-18 | 2009-09-08 | Siemens Aktiengesellschaft | Biomolecular contrast agents for therapy success and dose monitoring in radiation therapy with proton or ion beams |
JP2006248978A (en) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | New liposome preparation |
EP1957996A1 (en) * | 2005-11-29 | 2008-08-20 | Koninklijke Philips Electronics N.V. | Distinguishing bound and unbound contrast agents using magnetic resonance |
WO2007073792A1 (en) * | 2005-12-19 | 2007-07-05 | Bayer Schering Pharma Aktiengesellschaft | Process for preparing 4,4- diphenylcyclohexanol |
CN101528124A (en) | 2006-08-17 | 2009-09-09 | 艾佩斯制药公司 | Methods for lymph system imaging |
DE102006049821A1 (en) | 2006-10-18 | 2008-04-24 | Bayer Schering Pharma Aktiengesellschaft | New, well tolerated metal chelates, for use as radiodiagnostic, radiotherapeutic or NMR and X-ray diagnostic agents, contain chelator and perfluorinated polyethylene glycol residues |
US20100092389A1 (en) * | 2008-10-10 | 2010-04-15 | The General Hospital Corporation | Detection of atherosclerosis using indocyanine green |
WO2010048708A1 (en) * | 2008-10-27 | 2010-05-06 | The University Of Western Ontario | System and method for magnetic resonance imaging |
WO2010121133A2 (en) | 2009-04-17 | 2010-10-21 | The General Hospital Corporation | Multimodal imaging of fibrin |
AR075900A1 (en) | 2009-03-19 | 2011-05-04 | Wyeth Llc | METHODS FOR THE PREPARATION OF ACIDS (2- (8,9-DIOXO-2,6-DIAZABICICLIC (5.2.0) NON-1 (7) -EN-2-IL) ETIL) PHOSPHONIC AND ITS PRECURSORS. |
WO2011095898A1 (en) | 2010-02-02 | 2011-08-11 | Koninklijke Philips Electronics N.V. | Functional imaging |
TW201514188A (en) * | 2013-03-13 | 2015-04-16 | Lantheus Medical Imaging Inc | Process for manufacture of gadofosveset trisodium monohydrate |
WO2014165990A1 (en) | 2013-04-08 | 2014-10-16 | Sunnybrook Research Institute | System and method for imaging biomarkers indicative of cardiac thermal ablation lesions |
JP2015087167A (en) * | 2013-10-29 | 2015-05-07 | キヤノン株式会社 | Image processing method and image processing system |
WO2015089505A2 (en) | 2013-12-13 | 2015-06-18 | The Trustees Of The University Of Pennsylvania | Coaxial ablation probe and method and system for real-time monitoring of ablation therapy |
WO2015171543A1 (en) | 2014-05-05 | 2015-11-12 | California Institute Of Technology | Mutant akt-specific capture agents, compositions, and methods of using and making |
WO2015196208A2 (en) | 2014-06-20 | 2015-12-23 | The General Hospital Corporation | Collagen targeted imaging probes |
CN107624115B (en) | 2015-03-16 | 2021-10-26 | 加州理工学院 | Botulinum neurotoxin specific capture agents, compositions, methods of use, and methods of manufacture |
US10598671B2 (en) | 2015-07-15 | 2020-03-24 | Indi Molecular, Inc. | IL-17F-specific capture agents, compositions, and methods of using and making |
US10383590B2 (en) | 2015-09-28 | 2019-08-20 | General Electric Company | Methods and systems for adaptive scan control |
EP3519425B1 (en) | 2016-09-29 | 2024-02-28 | Indi Molecular, Inc. | Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same |
WO2018085375A1 (en) | 2016-11-01 | 2018-05-11 | Ohio State Innovation Foundation | Methods for the iodination of biomolecules |
US11719705B2 (en) | 2017-06-15 | 2023-08-08 | Indi Molecular, Inc. | IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making |
US11919972B2 (en) | 2018-11-02 | 2024-03-05 | Regeneron Pharmaceuticals, Inc. | Peptide libraries with non-canonical amino acids |
WO2020097531A1 (en) | 2018-11-08 | 2020-05-14 | Indi Molecular, Inc. | Theranostic capture agents, compositions, and methods of using and making |
US11414460B2 (en) | 2019-07-19 | 2022-08-16 | Institute For Systems Biology | KRAS-specific capture agents, compositions, and methods of making and using |
WO2022098743A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996023526A2 (en) * | 1995-02-01 | 1996-08-08 | Epix Medical, Inc. | Diagnostic imaging contrast agents with extended blood retention |
WO1997036619A2 (en) * | 1996-04-01 | 1997-10-09 | Epix Medical, Inc. | Bioactivated diagnostic imaging contrast agents |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5250285A (en) | 1985-05-08 | 1993-10-05 | The General Hospital Corporation | Hydroxy-aryl metal chelates for diagnostic NMR imaging |
US5094848A (en) | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
IT1269839B (en) | 1994-05-26 | 1997-04-15 | Bracco Spa | CONJUGATES OF BILIARY ACIDS, THEIR DERIVATIVES WITH METALLIC COMPLEXES AND RELATED USES |
CA2539215A1 (en) | 1995-02-01 | 1996-08-08 | Epix Pharmaceuticals, Inc. | Diagnostic imaging contrast agents with extended blood retention |
DE19529512C2 (en) | 1995-08-10 | 2000-11-23 | Siemens Ag | Phase contrast MR angiography method and arrangement for carrying out the method |
DE19543785A1 (en) | 1995-11-24 | 1997-05-28 | Philips Patentverwaltung | MR method and arrangement for carrying out the method |
IT1283650B1 (en) | 1996-08-02 | 1998-04-23 | Bracco Spa | HIGH RELAXATION PARAMAGNETIC CHELATES IN SERUM |
US5919967A (en) | 1997-04-11 | 1999-07-06 | Epix Medical, Inc. | Process for synthesizing phosphodiesters |
AU742438C (en) * | 1997-10-02 | 2003-05-22 | Lantheus Medical Imaging, Inc. | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies |
IT1304501B1 (en) | 1998-12-23 | 2001-03-19 | Bracco Spa | USE OF BILIARY ACID DERIVATIVES CONJUGATED WITH METALLIC COMPLEXES LIKE "BLOOD POOL AGENTS" FOR THE DIAGNOSTIC INVESTIGATION THROUGH RESONANCE |
-
1998
- 1998-09-24 AU AU96686/98A patent/AU742438C/en not_active Ceased
- 1998-09-24 CA CA002303426A patent/CA2303426C/en not_active Expired - Fee Related
- 1998-09-24 DK DK98950704T patent/DK1019094T3/en active
- 1998-09-24 NZ NZ503402A patent/NZ503402A/en unknown
- 1998-09-24 WO PCT/US1998/020182 patent/WO1999017809A2/en not_active Application Discontinuation
- 1998-09-24 JP JP2000514677A patent/JP2001518523A/en active Pending
- 1998-09-24 HU HU0101245A patent/HUP0101245A3/en unknown
- 1998-09-24 AT AT98950704T patent/ATE254479T1/en not_active IP Right Cessation
- 1998-09-24 ES ES98950704T patent/ES2206996T3/en not_active Expired - Lifetime
- 1998-09-24 IL IL13498598A patent/IL134985A0/en not_active IP Right Cessation
- 1998-09-24 EP EP98950704A patent/EP1019094B1/en not_active Expired - Lifetime
- 1998-09-24 SK SK484-2000A patent/SK4842000A3/en unknown
- 1998-09-24 BR BR9812716-0A patent/BR9812716A/en not_active Application Discontinuation
- 1998-09-24 DE DE69819925T patent/DE69819925T2/en not_active Expired - Lifetime
- 1998-09-24 KR KR1020007003527A patent/KR20010030854A/en not_active Application Discontinuation
- 1998-09-24 PT PT98950704T patent/PT1019094E/en unknown
-
2000
- 2000-03-10 IS IS5399A patent/IS2041B/en unknown
- 2000-04-03 NO NO20001707A patent/NO321966B1/en not_active IP Right Cessation
- 2000-09-08 US US09/887,706 patent/US6861045B1/en not_active Expired - Fee Related
-
2001
- 2001-01-12 HK HK01100360A patent/HK1030744A1/en not_active IP Right Cessation
-
2004
- 2004-10-08 US US10/961,872 patent/US7175829B2/en not_active Expired - Fee Related
-
2005
- 2005-09-22 JP JP2005276942A patent/JP2006077020A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996023526A2 (en) * | 1995-02-01 | 1996-08-08 | Epix Medical, Inc. | Diagnostic imaging contrast agents with extended blood retention |
WO1997036619A2 (en) * | 1996-04-01 | 1997-10-09 | Epix Medical, Inc. | Bioactivated diagnostic imaging contrast agents |
Non-Patent Citations (6)
Title |
---|
BRASCH R. ET AL.: "Assessing Tumor Angiogenisis Using Macromolecular MR Imaging Contrast Media", JOURNAL OF MAGNETIC RESONANCE IMAGING, vol. 7, no. 1, February 1997 (1997-02-01), pages 68 - 74, XP002094297 * |
DUPAS BENOIT ET AL.: "Delineation of Liver Necrosis Using Double Contrast-Enhanced MRI", JOURNAL OF MAGNETIC RESONANCE IMAGING, vol. 7, no. 3, 1997, pages 472 - 477, XP002094271 * |
HYNYNEN ET AL.: "The feasibility of using MRI to monitor and guide noninvasive ultrasound surgery.", ULTRASOUND IN MED. AND BIOL., vol. 19, no. 1, 1993, pages 91 - 92, XP002095678 * |
HYNYNEN K. ET AL.: "The Usefulness of a Contrast Agent and Gradient-Recalled Acquisition in a Steady-State Imaging Sequence for Magnetic Resonance Imaging-Guided Noninvasive Ultrasound Surgery", INVESTIGATIVE RADIOLOGY, vol. 29, no. 10, 1994, pages 897 - 903, XP002094270 * |
LAUFFER R B ET AL: "MS-325: A SMALL-MOLECULE VASCULAR IMAGING AGENT FOR MAGNETIC RESONANCE IMAGING", ACADEMIC RADIOLOGY, vol. 3, no. SUPPL. 02, August 1996 (1996-08-01), pages S356 - S358, XP000197827 * |
R.M.M. SEIBEL ET AL.: "Image-guided minimally invasive therapy", SURGICAL ENDOSCOPY, vol. 11, no. 2, 1997, pages 154 - 162, XP002095677 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9295737B2 (en) | 2002-03-01 | 2016-03-29 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
US9381258B2 (en) | 2002-03-01 | 2016-07-05 | Bracco Suisse S.A. | Targeting vector-phospholipid conjugates |
US9408926B2 (en) | 2002-03-01 | 2016-08-09 | Bracco Suisse S.A. | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US9446155B2 (en) | 2002-03-01 | 2016-09-20 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
Also Published As
Publication number | Publication date |
---|---|
EP1019094B1 (en) | 2003-11-19 |
WO1999017809A2 (en) | 1999-04-15 |
US20050118103A1 (en) | 2005-06-02 |
IS5399A (en) | 2000-03-10 |
PT1019094E (en) | 2004-03-31 |
AU742438C (en) | 2003-05-22 |
HUP0101245A3 (en) | 2003-10-28 |
DK1019094T3 (en) | 2004-02-16 |
NO321966B1 (en) | 2006-07-31 |
ATE254479T1 (en) | 2003-12-15 |
US7175829B2 (en) | 2007-02-13 |
CA2303426A1 (en) | 1999-04-15 |
EP1019094A2 (en) | 2000-07-19 |
AU9668698A (en) | 1999-04-27 |
DE69819925D1 (en) | 2003-12-24 |
HK1030744A1 (en) | 2001-05-18 |
NO20001707L (en) | 2000-05-31 |
AU742438B2 (en) | 2002-01-03 |
JP2006077020A (en) | 2006-03-23 |
BR9812716A (en) | 2000-08-22 |
NO20001707D0 (en) | 2000-04-03 |
ES2206996T3 (en) | 2004-05-16 |
KR20010030854A (en) | 2001-04-16 |
NZ503402A (en) | 2002-03-01 |
JP2001518523A (en) | 2001-10-16 |
IL134985A0 (en) | 2001-05-20 |
HUP0101245A2 (en) | 2001-08-28 |
SK4842000A3 (en) | 2000-11-07 |
IS2041B (en) | 2005-09-15 |
DE69819925T2 (en) | 2004-09-02 |
US6861045B1 (en) | 2005-03-01 |
CA2303426C (en) | 2008-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999017809A3 (en) | Contrast-enhanced diagnostic imaging method for monitoring interventional therapies | |
WO1997036619A3 (en) | Bioactivated diagnostic imaging contrast agents | |
EP1716871A3 (en) | Diagnostic imaging contrast agents with extended blood retention | |
AU1239300A (en) | Diagnostic medical ultrasound method and system for contrast agent imaging | |
EP1031354A3 (en) | Polymeric MRI Contrast agents | |
CA2190900A1 (en) | Medical device visible when using magnetic resonance imaging | |
WO1998018497A3 (en) | Contrast agents | |
WO2002078638A3 (en) | Morpholino imaging and therapy | |
AU1791895A (en) | Method of preventing hyperproliferative vascular disease | |
AU3594501A (en) | A method and system for guiding a diagnostic or therapeutic instrument towards atarget region inside the patient's body | |
AU3905099A (en) | Medical instrument and method for eye capsulotomy | |
AU9383098A (en) | Novel targeted contrast agents for diagnostic and therapeutic use | |
WO2001008711A3 (en) | Stable microbubbles for the use as an ultrasound contrast agent | |
AU2823795A (en) | 2,4,6-triiodo-5-substituted-amino-isophthalate esters useful as x-ray contrast agents for medical diagnostic imaging | |
AU3697899A (en) | Diagnostic agent for mr diagnosis | |
WO2003013616A8 (en) | Ionic and non-ionic radiographic contrast agents for use in combined x-ray and nuclear magnetic resonance diagnostics | |
WO2001040239A3 (en) | Transition metal-cyclopentadienyl-tropane conjugates | |
AU7178298A (en) | Magnetic resonance blood pool agents | |
WO2001087145A3 (en) | Screening system for inspecting a patient's retina | |
FR2766728B1 (en) | ANTI-VIBRATION DEVICE FOR BALL GAME INSTRUMENT | |
WO1998011921A3 (en) | Method | |
HU9400435D0 (en) | Method for testing driver`s behavior |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 134985 Country of ref document: IL |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 96686/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2303426 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 503402 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/002869 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4842000 Country of ref document: SK Ref document number: PV2000-1189 Country of ref document: CZ Ref document number: 1020007003527 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2000 514677 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998950704 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998950704 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-1189 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007003527 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2000-1189 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 96686/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998950704 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007003527 Country of ref document: KR |